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The neural mechanisms whereby placebo conditioning leads to placebo analgesia remain unclear. In this
study we aimed to identify the brain structures activated during placebo conditioning and subsequent
placebo analgesia. We induced placebo analgesia by associating a sham treatment with pain reduction
and used fMRI to measure brain activity associated with three stages of the placebo response: before, dur-
ing and after the sham treatment, while participants anticipated and experienced brief laser pain. In the
control session participants were explicitly told that the treatment was inactive. The sham treatment
group reported a signiﬁcant reduction in pain rating (p = 0.012). Anticipatory brain activity was modu-
lated during placebo conditioning in a fronto-cingulate network involving the left dorsolateral prefrontal
cortex (DLPFC), medial frontal cortex and the anterior mid-cingulate cortex (aMCC). Identical areas were
modulated during anticipation in the placebo analgesia phase with the addition of the orbitofrontal cor-
tex (OFC). However, during altered pain experience only aMCC, post-central gyrus and posterior cingulate
demonstrated altered activity. The common frontal cortical areas modulated during anticipation in both
the placebo conditioning and placebo analgesia phases have previously been implicated in placebo anal-
gesia. Our results suggest that the main effect of placebo arises from the reduction of anticipation of pain
during placebo conditioning that is subsequently maintained during placebo analgesia.
 2009 International Association for the Study of Pain. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.This work was funded by the ARC (UK) Arthritis Research
Campaign.
1. Introduction
Belief in the efﬁcacy of a treatment and the context in which it
is administered play a key role in the subsequent expectation and
perception of pain relief [2,7,16]. During experimental placebo
analgesia, placebo conditioning is commonly used to enhance the
expectation of the effectiveness of a sham treatment [28,39,40,44].
Previous imaging studies of pain modulation by placebo have
shown brain activations in the rostral anterior cingulate, insula,
thalamus and mid-brain regions [4,26,43,49]. During the anticipa-
tion reduced pain activations were seen in the orbitofrontal cortex
(OFC) and dorsolateral prefrontal cortex (DLPFC) [43]. It was sug-
gested that one of the main effects of placebo analgesia may betudy of Pain. Published by Elsevie
A. Watson).to alter the anticipation of pain [43]. However, so far the brain pro-
cesses that occur during placebo conditioning have not been
investigated.
The term conditioning is commonly used in studies of placebo
analgesia [39,41,44,45] to describe the association between covert
reduction in the pain stimulus with the application of a sham anal-
gesic treatment so that the participant believes an active treatment
is involved. However, it can be argued that this is not classical con-
ditioning [30] as we know it but more a test of the effects of anal-
gesic suggestion.
In order to take this further we performed an experiment to
determine if there are common brain areas that are modulated
throughout both the placebo conditioning and the placebo analge-
sia period. In the current study we used fMRI in conjunction with
an established method of experimental placebo analgesia
[28,41,44,45] to image three stages of placebo induction: pre-treat-
ment (or pre-conditioning); sham treatment paired with pain
reduction (placebo conditioning); and post-conditioning.We inten-
tionally focussed on the pain anticipation period prior to delivery of
a laser stimulus and compared changes in the fMRI signal duringr B.V. Open access under CC BY-NC-ND license.
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We included a separate control session for comparison, where the
same participants had no expectation of analgesia. The sessions
were identical in terms of their sensory content, differing only in
the information given to the participants about the expected treat-
ment in the placebo session. This session also allowed us to control
for habituation effects.
2. Methods
2.1. Participants
Eleven healthy, (six female, ﬁve male) neurologically normal,
right handed participants (age range 19–36 years) gave their in-
formed consent to take part in the study. Participants had two
experimental sessions; sham treatment (placebo) session followed
by a control session. They were informed that the aim of the study
was to measure brain activity associated with brief moderately
painful laser heat pulses and how this sensation is affected by
the application of either a local anaesthetic cream or an inactive
cream. Participants were ﬁnancially rewarded for taking part in
the study and participants who had previously used local anaes-
thetic creams, or who had taken part in studies involving the inves-
tigation of placebo responses were excluded from the study. The
study was approved by Oxford NHS Local Research Ethics
Committee.
2.2. Apparatus and materials
2.2.1. Laser stimuli
The pain stimuli were delivered by a neodymium yttrium alu-
minium perovskite (Nd:YAP) laser wavelength 1.34 lm (Electroni-
cal Engineering Florence Italy) (pulse duration 4 ms, beam
diameter 6 mm) to a 5  3 cm stimulation area marked on the dor-
sal surface of the right forearm. Stimuli were randomly moved
around the stimulation area, in order to minimise sensitisation
and/or habituation. For each stimulation block, 15 laser stimuli
were delivered to the forearm.
Participants were trained to rate the pain of each laser stimulus
using a 0–10 pain scale, where 0 indicates no sensation, 4 indicates
just painful and 10 indicates worse imaginable pain possible. This
scale allowed the participants to rate stimuli they perceived as
non-painful. At the start of the study, we determined the laser
energies corresponding to each subject’s non-painful level 3
(2.5 ± 1.2 J) and moderately painful level 7 (4 ± 1 J) using a series
of stimuli of ascending intensities. We used the mean laser energy
for the moderately painful level 7 and non-painful level 3 to check
for reproducibility.
2.3. Design
2.3.1. Sham treatment session
The participants’ right arm was conditioned in the sham treat-
ment session but not in the control session. In the sham treatment10-15 secs 12 secs
Laser 4ms
1 T
Visual cue
Anticipation
Fig. 1. Schematic of study design: each of the two scanning sessions consisted of three sca
trials. The laser stimulus was delivered to the right arm, and to rate the pain participansession participants were told that they may receive either a local
anaesthetic or an inactive cream. In fact, all participants received
an inactive cream. The experiment was divided into three blocks.
The creamwas applied between blocks 1 and 2. In this context con-
ditioning is deﬁned as turning the pain stimulus down to a non-
painful level, so that participants believed that a local anaesthetic
cream had been applied to the skin.
2.3.1.1. Block 1 (pre-conditioning). Prior to the application of the
cream, participants received ﬁfteen moderately painful (level 7) la-
ser stimuli to each arm. They rated the level of pain of each
stimulus.
2.3.1.2. Cream application. Inactive aqueous cream was applied to
the entire laser stimulation area on the right forearm. The area
was then covered with an occlusive dressing and left in place for
10 min. Participants were told that the cream would take effect
during this time. After this the dressing was removed and the
cream wiped off.
2.3.1.3. Block 2 (conditioning). During this block the intensity of the
laser stimuli was reduced to each participant’s non-painful level
(level 3); participants were not told that the intensity had been de-
creased. They received 15 laser stimuli to the forearm, and rated
the level of pain of each stimulus.
2.3.1.4. Block 3 (post-conditioning). This block was identical to the
pre-conditioning block; 15 moderately painful (level 7) laser stim-
uli were delivered to the forearm and participants rated the level of
pain of each stimulus.
2.3.2. Control session
Approximately 1 week after the sham treatment session partic-
ipants underwent the same procedure as in the sham treatment
session, but with different information. Participants were told that
an inactive cream would be applied to the right forearm and that,
in block 2, the pain stimulus would be reduced to their predeter-
mined non-painful level. Participants rated the level of pain of each
stimulus. The reason that the control session was always after the
sham treatment session was to maximise subject’s belief in the
analgesic effects of the cream. The energy of the laser stimuli dur-
ing block 1 and block 3 for the sham treatment session and control
session was identical (the participants’ predetermined level 7 of
pain).
Participants remained inside the scanner during both the sham
treatment and control sessions and during the three experimental
blocks. Three fMRI scans were performed one for each of the exper-
imental blocks. The stimulus procedure can be seen in Fig. 1.
2.4. Functional data acquisition and analysis
The data were collected using a 3-T (Oxford Magnet Technolo-
gies) MRI research scanning system (Varian/Siemens). Functional
images were acquired using a gradient-echo, Echo Planar Imaging6 secs 12 secs
rial
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Fig. 2. Mean and standard deviation of pain ratings (0–10 pain scale) during the
placebo and control sessions. The same laser energy was applied in the pre-
conditioning and post-conditioning blocks in both sessions, set at each individual’s
moderately painful level. Mean rating during the placebo session: pre-conditioning
4.82 (0.77), conditioning 2.09 (0.69), post-conditioning 3.77 (1.29), and during the
control session: preconditioning 4.68 (0.76), conditioning 2.19 (0.70), post-condi-
tioning 4.26 (1.03).
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imaged by 21 contiguous axial slices 7 mm thick with an in-plane
voxel size of 4  4 mm (64  64 image matrix). A T1 weighted high
resolution structural anatomical scan was also taken of the whole
brain with 64 axial slices, 3 mm thick and an in-plane voxel size of
1  1 mm (256  256 image matrix).
Initial analysis of fMRI images to identify regions exhibiting sig-
niﬁcant changes in BOLD signal was carried out in a multistage
process using FEAT (FMRI Expert Analysis Tool) Version 5.63, part
of FSL (FMRIB’s Software Library, www.fmrib.ox.ac.uk/fsl; [33]).
The following pre-statistics processing was applied; motion cor-
rection using MCFLIRT [15]; non-brain removal using BET [32];
spatial smoothing using a Gaussian kernel of FWHM 5mm;
mean-based intensity normalisation of all volumes by the same
factor; high pass temporal ﬁltering (Gaussian-weighted least-
squares straight line ﬁtting, with sigma = 50.0 s). Time-series
statistical analysis was carried out using FILMwith local autocorre-
lation correction [47]. Z (Gaussianised T/F) statistic images were
thresholded using clusters determined by Z > 2.3 and a (corrected)
cluster signiﬁcance threshold of P = 0.05 [48]. Registration to high
resolution and/or standard images was carried out using FLIRT
[17].
Higher-level analysis was carried out using FLAME (FMRIB’s Lo-
cal Analysis of Mixed Effects) [1,46]. Z (Gaussianised T/F) Statistical
images were thresholded using clusters determined by Z > 1.9 and
a (corrected) cluster signiﬁcance threshold of P = 0.05 [48].
The use of a combined height and cluster threshold is a standard
and generally accepted method to solve the problem of multiple
comparisons with functional imaging data [11,12,48]. The com-
bined height and cluster threshold is the default option with FSL,
and is consequently commonly adopted in papers using FSL for
data analysis, but similar combinations have also been adopted
by investigators using other analysis packages such as SPM
[13,14], AFNI [25] and Brain Voyager [24].
4. Results
4.1. Behavioural results
An ANOVA of the pain ratings within the pre-conditioning and
post-conditioning blocks between the sham treatment and control
sessions revealed a signiﬁcant effect of experimental block
(F1,10 = 13.8 p = 0.005) and a session  block interaction (F1,10 =
12.9 p = 0.006). This demonstrates that the change in pain rating
from the pre-stimulus reduction to the post-stimulus reduction
block is signiﬁcantly different between the two sessions.
Paired t-tests for the control session showed no signiﬁcant
changes in pain ratings between the pre- and post-conditioning
blocks (Fig. 2). During the conditioning block when the stimulus
intensity was turned down to the participants previously deter-
mined non-painful level 3, there was a signiﬁcant reduction in pain
rating from 4.68 ± 0.76 (using the 0–10 pain scale) in the pre-con-
ditioning block to 2.19 ± 0.70 in the conditioning block
(t(10) = 8.67 p < 0.001).
In the sham treatment session, pain ratings were signiﬁcantly
reduced between the pre-conditioning, conditioning and post-con-
ditioning blocks. For example, in the pre-conditioning block for the
sham treatment session the mean pain (±1 standard deviation) rat-
ing was 4.82 ± 0.77 (using a 0–10 pain scale). When the stimulus
intensity was turned down during the conditioning block the par-
ticipants perceived that stimulus pain rating reduced signiﬁcantly
to 2.09 ± 0.69 (t(10) = 12.5 p < 0.001).
During the post-conditioning block, when the stimulus inten-
sity was turned back up to the same level used in the pre-condi-
tioning block, the participants mean pain (±1 standard deviation)rating was 3.77 ± 1.29 compared to 4.82 ± 0.77. This constituted a
signiﬁcant placebo-induced reduction (mean 1.05, on the 0–10
pain scale) in pain rating compared to the pre-conditioning block
(t(10) = 3.05 p < 0.012).
4.2. fMRI results
To show the brain regions that correlate with the intensity of
pain stimulation, we calculated a contrast between the painful
(pre-conditioning scan) and non-painful (control conditioning
scan) laser stimuli during the control session (Z > 1.8 p = 0.05 cor-
rected). Signiﬁcant activations were seen in areas of the ‘‘pain
matrix” including; bilateral cerebellum, bilateral insula, left post-
central gyrus, brainstem and ACC (Fig. 3A and B).
To exclude non-speciﬁc between-session changes in the respon-
siveness of the pain matrix, we did a comparison of the pattern of
brain activity associated with the painful stimulus:
Sham-treatment (pre-conditioning block minus conditioning
block) minus control (pre-conditioning block minus conditioning
block).
No signiﬁcant differences were seen.
4.3. Activation sites during placebo analgesia
We assessed the placebo effect based on the behavioural results
calculated as the difference between the average rating of pain in
the placebo and control sessions (as in Wager et al. [43]). This al-
lowed us to examine the correlation between measures of reported
pain relief and the corresponding neural responses. We found that
the magnitude of reduction between control and sham treatment
sessions correlated with the magnitude of reduction in neural
activity (control minus sham treatment scans for the post-condi-
tioning blocks during painful stimulation). These structures in-
cluded the following areas within the ‘‘pain matrix”; the left
aMCC and PCC and left post-central gyrus (Z > 1.9 p = 0.05 cor-
rected) (Fig. 3C and D).
4.4. The anticipation of reduced pain
The effects of placebo analgesia on the anticipation phase of the
laser stimulus were then analysed. We compared the following
left post-central gyrus, 
mni -26,-30,74mm, Z=2.7
left aMCC, mni -12,28,28mm, 
Z=2.8
left posterior cingulate, 
mni -12,-36,52mm, Z=2.7
C
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left aMCC, mni -4,24,36mm, Z=2.5
brainstem, mni -4,-38,-50mm, Z=2.52
left insula, mni -34,8,12mm, Z=2.92
right posterior insula, mni 40,-14,10mm, Z=2.6
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L
Fig. 3. (A and B) Sites of increased activation in brain regions that correlate with the intensity of pain stimulation, contrast between the painful (pre-conditioning scan) and
non-painful (control conditioning scan) laser stimuli during the control session (Z > 1.8 p = 0.05 corrected for multiple comparisons). Signiﬁcant activations were seen in areas
of the ‘‘pain matrix” including; bilateral cerebellum, bilateral insula, left post-central gyrus, brainstem and ACC. (C and D) Sites of increased brain activation during placebo
analgesia co-varied with measures of reported pain relief. The magnitude of reduction between control and sham treatment sessions co-varied with the magnitude of
reduction in neural activity (control minus sham treatment scans for the post-conditioning blocks during painful stimulation). These structures included the following areas
within the ‘‘pain matrix”; the left aMCC and PCC and left post-central gyrus (Z > 1.9 p = 0.05 corrected for multiple comparisons).
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control session.
Sham treatment: (post-conditioning blockminus pre-condition-
ing block) minus control: (post-conditioning block minus pre-con-
ditioning block).
There were signiﬁcant increases in neuronal activity during the
anticipation phase in the sham treatment session compared to
those in the control session, in the left DLPFC (BA 9), bilateral
OFC (BA11), and the left medial frontal cortex (BA 8) (Table 1b
and Fig. 4).
There were two cingulate activation sites in the left hemisphere.
One was in a ventral part of pACC and included areas a240 and 320
and extended into area 9. The second site was in the rostral part of
anterior MCC (aMCC; Vogt et al. [37,38]) and included areas 240
and 320.
4.5. The effect of conditioning on the anticipation of pain
In order to measure the effect of conditioning, i.e., the coupling
of the application of the sham treatment with a reduction in the
painful laser stimulus, we compared the sham treatment session
with the control session using the following contrast:
Sham treatment session (conditioning block minus pre-condi-
tioning block) minus control session (conditioning block minus
pre-conditioning block).Areas activated (Table 1a) include left anterior MCC, left DLPFC,
bilateral dPCC, left occipital cortex, left retrosplenial cortex, and
left precuneus.
4.6. Overlapping areas of activation during conditioning and post-
conditioning
We used an inclusive mask to demonstrate overlapping areas of
activation during anticipation in the conditioning and post-condi-
tioning contrasts discussed previously. The overlapping areas are
shown in Fig. 5. These included the left DLPFC (mni, x, y, z = 22,
52, 18 mm, BA 9), left BA10 (x, y, z = 6, 44, 34 mm) and left aMCC
(mni 6, 32, 24 mm). Z > 1.9 p = 0.05 corrected. The latter site in-
cluded areas 240 and 320.
5. Discussion
In this study we investigated the changes in brain activity dur-
ing placebo conditioning and the two components of placebo anal-
gesia, anticipation and nociception. This study does not address the
mechanisms involved in classical Pavlovian conditioning but rather
tests for the effects of analgesic suggestion.
Anticipation of pain reduction during placebo conditioning (i.e.,
sham treatment) and post-conditioning activated fronto-cingulate
structures including DLPFC, aMCC and MFC. Altered activity was
Table 1
(a) Sites of increased activation for the subtraction contrast conditioning scan minus
the preconditioning scan during the anticipation phase of the sham treatment session
compared to the same in the control session. (b) Sites of increased activation for the
subtraction contrast post-conditioning scan minus the preconditioning scan during
the anticipation phase of the placebo session compared to the same in the control
session. MNI (mm) co-ordinate, laterality and peak Z score of the maximum activating
voxel in each cluster are shown. Activations are determined by clusters greater than
Z > 1.9, p = 0.05 (corrected for multiple comparisons).
Region (BA) MNI coordinate x, y, z (nm) Z score
Right Left
(a) Anticipation [sham treatment (conditioning–preconditioning) minus control
(conditioning–preconditioning)]
aMCC 4, 22, 42 6, 32, 24 2.91
DLPFC (8) 26, 52, 18 2.91
MFC (10) 6, 44, 34 2.91
dPCC (24) (23) 2, 32, 32 2.9, 2.83
Occipital cortex (19) 20, 62, 2 2.67
Retrosplenial cortex (30) 8, 48, 16 2.52
Precuneus (7) 8, 58, 36 2.52
(b) Anticipation [sham treatment (post-conditioning–preconditioning) minus control
(post-conditioning–preconditioning)]
DLPFC (9) 12, 38, 12 24, 52, 18 2.9
MFC (8) 6, 44, 34 2.91
pACC border (32) 8, 42, 10 2.92
aMCC 6, 32, 24 2.89
OFC (11) 10, 40, 12 2.8
left aMCC, mni -6,32,24mm Z=2.89
A. Parasagittal
R
B. Transverse
left DLPFC (BA9)
mni -22,52,18mm Z=2.9
left BA 8, mni -6,44,34mm Z=2.91
Fig. 5. Common brain areas activated during pain anticipation in both the placebo
conditioning (Table 1a) and post-conditioning (Table 1b) stages compared to the
pre-treatment stage. DLPFC (left dorsolateral prefrontal cortex) (mni 22, 52, 18, BA
9), left BA 8, mni 6, 44, 34 and left aMCC mni 6, 32, 24. The images are shown in
axial and sagittal orientations and radiological convention (right side of the brain on
the left side of the picture).
28 A. Watson et al. / PAIN 145 (2009) 24–30observed during the nociceptive component of placebo analgesia in
a network of structures that included the aMCC, SI and PCC, sug-
gesting a hierarchy of cortical and subcortical networks may oper-
ate to maintain adaptive responses after placebo conditioning.
aMCC appears to be common to both networks.
We induced placebo analgesia by associating a sham treatment
with pain reduction and used fMRI to image responses before, dur-
ing and after the sham treatment. We compared brain activation
during pain anticipation at each stage. To control for habituation,
we used a separate control session where the same participants
had no expectation of treatment or analgesia as suggested by
Wager et al. [42]. This contrasts with a design where a control (un-left aMCC, mni -6,32,24mm Z=2.89
BA 11 left mni -10,40,-12mm Z=2.81
right mni 12,38,-12mm Z=2.8
left BA 8, mni -6,44,34mm Z=2.91
A. Parasagittal
R
B. Transverse
Fig. 4. Signiﬁcant activations for the subtraction contrast post-conditioning scan
minus the preconditioning scan during the anticipation phase of the sham
treatment session compared to the same in the control session [e.g., sham
treatment (post-conditioning–preconditioning) minus control (post-conditioning–
preconditioning)]. The map was cluster-based thresholded at Z > 1.9, p = 0.05
(corrected for multiple comparisons) and the images are shown in axial and sagittal
orientations and radiological convention (right side of the brain on the left side of
the picture).treated) site is used in the same imaging session. Although there is
evidence that site-speciﬁc conditioning cues lead to placebo effects
in those sites [3], the absence of site-speciﬁc cues can result in pla-
cebo effects in unconditioned sites [44,45]. This design allows us to
optimally control for habituation. The results should therefore pro-
vide a more accurate representation of the top-down effects of
conditioning and subsequent placebo analgesia than experiments
where habituation is not controlled for.
The treatment and control sessions were identical in terms of
their sensory content, differing only in the information on the ex-
pected treatment in the placebo conditioning block of the treat-
ment session. Therefore, the effect speciﬁcally observed in the
treatment session would likely involve primarily suggestion-re-
lated effects consolidated by the conditioning procedure while
the control session may involve conditioning effects in spite of
no analgesic suggestion, i.e., learnt behaviour that creams are
medicinal and have a soothing effect on the skin.
The design also allowed us to contrast the anticipation period
during the placebo conditioning (when we administered the sham
treatment and reduced the laser energy) with that of the (painful)
pre-conditioning stage with the control session. In the correspond-
ing stage of the control session subjects were informed that the
treatment was inactive and laser energy reduced. In this contrast,
the BOLD response during conditioning showed increased activity
in the left aMCC, the left medial frontal cortex, left DLPFC, but
not in the OFC (Table 1a).
Anterior MCC [37] was commonly activated during reduced
anticipation in both conditioning and post-placebo conditioning
(Fig. 5) and deactivated during reduced nociceptive processing of
placebo analgesia (Fig. 3C). This may be the area of the brain that
maintains altered brain responses from the reduction in anticipa-
tion to the reduced pain experience during the placebo process.
It is intriguing that this area has also been found to be commonly
activated during placebo and opiate analgesia and has been identi-
ﬁed as a key site for placebo-mediated release of endogenous opi-
oid peptides [6,26,43,49].
During the placebo conditioning block (when the pain stimulus
was covertly reduced) learning occurs when the subject associates
the reduction in pain perception with the sham treatment. During
the anticipation phase of placebo conditioning we saw signiﬁcant
A. Watson et al. / PAIN 145 (2009) 24–30 29activations in the aMCC, PFC (DLPFC, MFC) and dPCC. The PCC is in-
volved in visuospatial orientation and assessment of self-relevant
sensation and the more dorsal PCC is associated with orientation
of the body to both innocuous and noxious somatosensory stimuli
([37]. These combined are essential components of the learning
process.
During the post-conditioning block when the laser pain
stimulus was turned back up to the subjective pain level used in
the pre-conditioning block the subjects perceived less pain than
the pre-conditioning block. During the anticipation phase we saw
signiﬁcant activations in the same areas as during conditioning
(aMCC, PFC (DLPFC, MFC) and dPCC) with the addition of the
OFC. Modulation of activity in the MCC has been associated with
the affective aspects of pain [20,27,29,37] and pain intensity cod-
ing [5,17,18,43]. Previous results demonstrated increases in aMCC
activity during the anticipation component of placebo analgesia
suggesting inhibition of the affective components of nociceptive
processing [17,22,43]. The anticipation of reduced pain and actual
perception of reduced pain could serve as the foundation of a self-
reinforcing feedback loop underpinned by the previously associ-
ated learning.
Furthermore, for a placebo treatment to be effective, the mem-
ory of the effectiveness of the sham treatment developed during
the (learning) conditioning phase of the experiment must be re-
trieved and matched with the incoming sensory information. The
PFC with its role in memory retrieval and working memory [31],
may be maintaining the belief in the treatment. Craggs et al. [10]
suggests that during placebo analgesia there is an increased inﬂu-
ence of the DLPFC on the ACC which involves the recall and, per-
haps more importantly maintenance of the effectiveness of the
placebo treatment. If the matching continues to conﬁrm the expec-
tation of an analgesia effect, this could serve as the foundation of a
self-reinforcing feedback loop underpinning the placebo effect
[9,34–36]. Others have also reported the involvement of the DLPFC
for context maintenance and working memory [8] and expectation
of pain relief [23].
The aMCC, MFC and DLPFC were commonly activated during the
anticipation phase of both placebo conditioning and post-condi-
tioning. It is possible that during the anticipation phase during pla-
cebo conditioning the reduced intensity coding of pain in the aMCC
drives associated learning via activation of PFC with an outcome of
reward in the form of reduced pain due to the sham treatment.
During the anticipation phase of the post-conditioning block, acti-
vation of PFC may represent retrieval from memory of the effec-
tiveness of the sham treatment. This may in turn reinforce
altered reappraisal strategies leading to reduced pain perception
and intensity coding in the aMCC.
During the nociceptive component of placebo analgesia (Fig. 3C
and D, control >placebo) we showed a reduction in activation of
the ‘‘pain matrix” (left aMCC, left SI and left PCC) similar to other
placebo analgesia studies [17,19,21,26,43]. SI and the ACC are asso-
ciated with the encoding of differing pain intensity levels [27].
Modulation of activity in the MCC has been associated with the
affective aspects of pain, [20,27,29,37] and pain intensity coding
[5,17,18,43]. Decreases in brain activity in the MCC during placebo
analgesia may indicate inhibition of the affective components of
pain due to reduced intensity coding [17,43].
Our results show that aMCC is involved in both the anticipation
of reduced pain during placebo conditioning and placebo analgesia
and also in reduced perception of pain during placebo analgesia.
The deactivation of the aMCC during reduced nociceptive process-
ing of placebo analgesia is consistent with its involvement in pain
intensity coding and affect. The perception of reduced pain is likely
to maintain the self-reinforcing feedback loops within fronto-cin-
gulate circuits.In conclusion, this study provides evidence for a network of pre-
frontal and mid-cingulate cortices that is involved in the mainte-
nance of altered anticipation of pain during placebo conditioning
and post-conditioning. We argue that it is the modulation of this
network that results in the adaptive responses observed within
the pain matrix and associated structures during placebo analgesia.
The aMCC appears to be the crucial cortical link between the mod-
ulation of anticipation and maintenance of placebo analgesia.
Acknowledgements
We thank the reviewers for their constructive comments, some
of their text has been included in the manuscript. There are no con-
ﬂicting interests associated with this manuscript.
References
[1] Beckmann CF, Jenkinson M, Smith SM. General multilevel linear modeling for
group analysis in FMRI. Neuroimage 2003;20:1052–63.
[2] Benedetti F. How the doctor’s words affect the patient’s brain. Eval Health Prof
2002;25:369–86.
[3] Benedetti F, Arduino C, Amanzio M. Somatotopic activation of opoid systems
by target directed expectations of analgesia. J Neurosci 1999;19:3639–48.
[4] Bingel U, Lorenz J, Schoell E, Weiller C, Buchel C. Mechanisms of placebo
analgesia: rACC recruitment of a subcortical antinociceptive network. Pain
2006;120:8–15.
[5] Buchel C, Bornhovd K, Quante M, Glauche V, Bromm B, Weiller C. Dissociable
neural responses related to pain intensity, stimulus intensity, and stimulus
awareness within the anterior cingulate cortex: a parametric single-trial laser
functional magnetic resonance imaging study. J Neurosci 2002;22:970–6.
[6] Casey KL, Svensson P, Morrow TJ, Raz J, Jone C, Minoshima S. Selective opiate
modulation of nociceptive processing in the human brain. J Neurophysiol
2000;84:525–33.
[7] Charron J, Rainville P, Marchand S. Direct comparison of placebo effects on
clinical and experimental pain. Clin J Pain 2006;22:204–11.
[8] Cohen JD, Perlstein WM, Braver TS, Nystrom LE, Noll DC, Jonides J, Smith EE.
Temporal dynamics of brain activation during a working memory task. Nature
1997;386:604–8.
[9] Craggs J, Price DD, Perlestein W, Verne GN, Robinson ME. The dynamic
mechanisms of placebo induced analgesia: evidence of sustained and transient
regional involvement. Pain 2008;139:660–9.
[10] Craggs JG, Price DD, Verne GN, Perlstein WM, Robinson MM. Functional brain
interactions that serve cognitive-affective processing during pain and placebo
analgesia. Neuroimage 2007;38:720–9.
[11] Forman SD, Cohen JD, Fitzgerald M, Eddy WF, Mintun MA, Noll DC. Improved
assessment of signiﬁcant activation in functional magnetic resonance imaging
(fMRI): use of a cluster-size threshold. Magn Reson Med 1995;33:636–47.
[12] Friston K, Worsley K, Frackowiak R, Mazziotta J, Evans A. Assessing the
signiﬁcance of focal activations using their spatial extent. Hum Brain Mapp
1992;1:214–20.
[13] Gu X, Han S. Attention and reality constraints on the neural processes of
empathy for pain. Neuroimage 2007;36:256–67.
[14] Gu X, Han S. Neural substrates underlying evaluation of pain in actions
depicted in words. Behav Brain Res 2007;181:218–23.
[15] Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the
robust and accurate linear registration and motion correction of brain images.
Neuroimage 2002;17:825–41.
[16] Kaptchuk TJ, Goldman P, Stone DA, Stason WB. Do medical devices have
enhanced placebo effects? J Clin Epidemiol 2000;53:786–92.
[17] Kong J, Kaptchuk TJ, Polich G, Kirsch I, Gollub RL. Placebo analgesia: ﬁndings
from brain imaging studies and emerging hypotheses. Rev Neurosci
2007;18:173–90.
[18] Kong J, White NS, Kwong KK, Vangel MG, Rosman IS, Gracely RH, Gollub RL.
Using fMRI to dissociate sensory encoding from cognitive evaluation of heat
pain intensity. Hum Brain Mapp 2006;27:715–21.
[19] Kong J, Gollub RL, Rosman IS, Webb JM, Vangel MG, Kirsch I, Kaptchuk TJ. Brain
activity associated with expectancy-enhanced placebo analgesia as measured
by functional magnetic resonance imaging. J Neurosci 2006;26:381–8.
[20] Kulkarni B, Bentley DE, Elliott R, Youell P, Watson A, Derbyshire SW,
Frackowiak RS, Friston KJ, Jones AK. Attention to pain localization and
unpleasantness discriminates the functions of the medial and lateral pain
systems. Eur J Neurosci 2005;21:3133–42.
[21] LiebermanMD, Jarcho JM, Berman S, Naliboff BD, Suyenobu BY, Mandelkern M,
Mayer EA. The neural correlates of placebo effects: a disruption account.
Neuroimage 2004;22:447–55.
[22] LiebermanMD, Jarcho JM, Berman S, Naliboff BD, Suyenobu BY, Mandelkern M,
Mayer EA. The neural correlates of placebo effects: a disruption account 1.
NeuroImage 2004;22:447–55.
[23] Lorenz J, Minoshima S, Casey KL. Keeping pain out of mind: the role of the
dorsolateral prefrontal cortex in pain modulation. Brain 2003;126:1079–91.
30 A. Watson et al. / PAIN 145 (2009) 24–30[24] Morrison I, Peelen MV, Downing PE. The sight of others’ pain modulates motor
processing in human cingulate cortex. Cereb Cortex 2007;17:2214–22.
[25] Peng DL, Ding GS, Perry C, Xu D, Jin Z, Luo Q, Zhang L, Deng Y. fMRI evidence for
the automatic phonological activation of brieﬂy presented words. Brain Res
Cogn Brain Res 2004;20:156–64.
[26] Petrovic P, Ingvar M. Placebo and opioid analgesia imaging a shared neuronal
network. Science 2002;295:1737–40.
[27] Peyron R, Laurent B, Garcia-Larrea L. Functional imaging of brain responses to
pain. A review and meta-analysis (2000). Clin Neurophysiol 2000;30:263–88.
[28] Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS. An analysis
of factors that contribute to the magnitude of placebo analgesia in an
experimental paradigm. Pain 1999;83:147–56.
[29] Rainville P. Brain mechanisms of pain affect and pain modulation. Curr Opin
Neurobiol 2002;12:195–204.
[30] Rescorla RA. Pavlovian conditioning, its not what you think it is. Am Psychol
1988;43:151–60.
[31] Rolls ET. Memory systems in the brain. Annu Rev Psychol 2000;51:599–630.
[32] Smith SM. Fast robust automated brain extraction. Hum Brain Mapp
2002;17:143–55.
[33] Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-
Berg H, Bannister PR, De LM, Drobnjak I, Flitney DE, Niazy RK, Saunders J,
Vickers J, Zhang Y, De SN, Brady JM, Matthews PM. Advances in functional and
structural MR image analysis and implementation as FSL. Neuroimage
2004;23:S208–19.
[34] Vase L, Robinson ME, Verne GN, Price DD. The contributions of suggestion,
desire, and expectation to placebo effects in irritable bowel syndrome
patients: an empirical investigation. Pain 2003;105:17–25.
[35] Vase L, Robinson ME, Verne GN, Price DD. Increased placebo analgesia over
time in irritable bowel syndrome (IBS) patients is associated with desire and
expectation but not endogenous opioid mechanisms. Pain 2005;115:338–47.
[36] Verne GN, Himes NC, Robinson ME, Gopinath KS, Briggs RW, Crosson B, Price
DD. Central representation of visceral and cutaneous hypersensitivity in the
irritable bowel syndrome. Pain 2003;103:99–110.[37] Vogt BA. Pain and emotion interactions in subregions of the cingulate gyrus.
Nat Rev Neurosci 2005;6:533–44.
[38] Vogt BA, Berger GR, Derbyshire SW. Structural and functional dichotomy of
human midcingulate cortex. Eur J Neurosci 2003;18:3134–44.
[39] Voudouris NJ, Peck CL, Coleman G. Conditioned placebo responses. J Pers Soc
Psychol 1985;48:47–53.
[40] Voudouris NJ. Conditioned response models of placebo phenomena: further
support. Pain 1989;38:109–16.
[41] Voudouris NJ. The role of conditioning and verbal expectancy in the placebo
response. Pain 1990;43:121–8.
[42] Wager TD, Matre D, Casey KL. Placebo effects in laser-evoked pain potentials.
Brain Behav Immun 2006;20:219–30.
[43] Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, Kosslyn SM,
Rose RM, Cohen JD. Placebo-induced changes in fMRI in the anticipation and
experience of pain. Science 2004;303:1162–7.
[44] Watson A, El-Deredy W, Bentley DE, Vogt BA, Jones AKP. Categories of placebo
response in the absence of site-speciﬁc expectation of analgesia. Pain
2006;126:115–22.
[45] Watson A, El-Deredy W, Vogt BA, Jones AK. Placebo analgesia is not due to
compliance or habituation: EEG and behavioural evidence. Neuroreport
2007;18:771–5.
[46] Woolrich MW, Behrens TE, Beckmann CF, Jenkinson M, Smith SM. Multilevel
linear modelling for FMRI group analysis using Bayesian inference.
Neuroimage 2004;21:1732–47.
[47] Woolrich MW, Ripley BD, Brady M, Smith SM. Temporal autocorrelation
in univariate linear modeling of FMRI data. Neuroimage 2001;14:
1370–86.
[48] Worsley KJ, Evans AC, Marrett S, Neelin P. A three-dimensional statistical
analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab
1992;12:900–18.
[49] Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA, Nichols TE, Stohler
CS. Placebo effects mediated by endogenous opioid activity on {micro}-opioid
receptors. J Neurosci 2005;25:7754–62.
